[2] In 1892, Russell Henry Chittenden, assisted by Elliott P. Joslin and Frank Sherman Meara, investigated the matter more completely,[3] and called it 'bromelin'.
[4][5] The starting material is blended and pressed through a filter to obtain a supernatant liquid containing the soluble bromelain enzyme.
[6] The proteolytic activity of concentrated bromelain solutions remains relatively stable for at least 1 week at room temperature, and multiple freeze-thaw cycles or exposure to the digestive enzyme trypsin have little effect on it.
[4][8] A concentrate of proteolytic enzymes enriched in bromelain is approved in Europe for the debridement (removal of dead tissue) of severe burn wounds under the trade name NexoBrid.
[1] Bromelain has not been scientifically proven to be effective in treating any other diseases and it has not been approved by the U.S. Food and Drug Administration for the treatment of any disorder.
While there have been studies which positively correlated the use of bromelain with reduction of symptom severity in osteoarthritis,[9][10] "[t]he majority of the studies have methodological issues that make it difficult to draw definite conclusions", as none definitively established efficacy, recommended dosage, long term safety, or adverse interaction with other medications.